895 related articles for article (PubMed ID: 26537877)
1. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes.
Chaudhari U; Nemade H; Gaspar JA; Hescheler J; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Dec; 90(12):3087-3098. PubMed ID: 26842497
[TBL] [Abstract][Full Text] [Related]
3. Metabolite signatures of doxorubicin induced toxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Chaudhari U; Ellis JK; Wagh V; Nemade H; Hescheler J; Keun HC; Sachinidis A
Amino Acids; 2017 Dec; 49(12):1955-1963. PubMed ID: 28421296
[TBL] [Abstract][Full Text] [Related]
4. Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes.
Chaudhari U; Nemade H; Sureshkumar P; Vinken M; Ates G; Rogiers V; Hescheler J; Hengstler JG; Sachinidis A
Arch Toxicol; 2018 Jan; 92(1):371-381. PubMed ID: 28940058
[TBL] [Abstract][Full Text] [Related]
5. Bringing in vitro analysis closer to in vivo: Studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling.
Verheijen M; Schrooders Y; Gmuender H; Nudischer R; Clayton O; Hynes J; Niederer S; Cordes H; Kuepfer L; Kleinjans J; Caiment F
Toxicol Lett; 2018 Sep; 294():184-192. PubMed ID: 29803840
[TBL] [Abstract][Full Text] [Related]
6. Screening, verification, and analysis of biomarkers for drug-induced cardiac toxicity in vitro based on RTCA coupled with PCR Array technology.
Zhang L; Xu MX; Yin QS; Zhu CY; Cheng XL; Ren YR; Zhuang PW; Zhang YJ
Toxicol Lett; 2017 Feb; 268():17-25. PubMed ID: 28099878
[TBL] [Abstract][Full Text] [Related]
7. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.
Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y
Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302
[TBL] [Abstract][Full Text] [Related]
8. Anthracycline-Induced Cardiotoxicity: Molecular Insights Obtained from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).
Bozza WP; Takeda K; Alterovitz WL; Chou CK; Shen RF; Zhang B
AAPS J; 2021 Mar; 23(2):44. PubMed ID: 33719006
[TBL] [Abstract][Full Text] [Related]
9. Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.
Clements M; Millar V; Williams AS; Kalinka S
Toxicol Sci; 2015 Nov; 148(1):241-60. PubMed ID: 26259608
[TBL] [Abstract][Full Text] [Related]
10. Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells.
Nemade H; Chaudhari U; Acharya A; Hescheler J; Hengstler JG; Papadopoulos S; Sachinidis A
Arch Toxicol; 2018 Apr; 92(4):1507-1524. PubMed ID: 29397400
[TBL] [Abstract][Full Text] [Related]
11. Assessment of acute and chronic toxicity of doxorubicin in human induced pluripotent stem cell-derived cardiomyocytes.
Louisse J; Wüst RCI; Pistollato F; Palosaari T; Barilari M; Macko P; Bremer S; Prieto P
Toxicol In Vitro; 2017 Aug; 42():182-190. PubMed ID: 28456566
[TBL] [Abstract][Full Text] [Related]
12. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells.
Holmgren G; Synnergren J; Bogestål Y; Améen C; Åkesson K; Holmgren S; Lindahl A; Sartipy P
Toxicology; 2015 Feb; 328():102-11. PubMed ID: 25529476
[TBL] [Abstract][Full Text] [Related]
14. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.
Burridge PW; Li YF; Matsa E; Wu H; Ong SG; Sharma A; Holmström A; Chang AC; Coronado MJ; Ebert AD; Knowles JW; Telli ML; Witteles RM; Blau HM; Bernstein D; Altman RB; Wu JC
Nat Med; 2016 May; 22(5):547-56. PubMed ID: 27089514
[TBL] [Abstract][Full Text] [Related]
15. Anthracyclines induce cardiotoxicity through a shared gene expression response signature.
Matthews ER; Johnson OD; Horn KJ; Gutiérrez JA; Powell SR; Ward MC
PLoS Genet; 2024 Feb; 20(2):e1011164. PubMed ID: 38416769
[TBL] [Abstract][Full Text] [Related]
16. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Kopljar I; Gallacher DJ; De Bondt A; Cougnaud L; Vlaminckx E; Van den Wyngaert I; Lu HR
Stem Cells Transl Med; 2016 May; 5(5):602-12. PubMed ID: 27034410
[TBL] [Abstract][Full Text] [Related]
17. Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro.
Fortin MC; LaCroix AS; Grammatopoulos TN; Tan L; Wang Q; Manca D
Sci Rep; 2023 Nov; 13(1):21054. PubMed ID: 38030645
[TBL] [Abstract][Full Text] [Related]
18. Pediatric Anthracycline-Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem-Cell Modeling.
Tripaydonis A; Conyers R; Elliott DA
Clin Pharmacol Ther; 2019 Mar; 105(3):614-624. PubMed ID: 30460992
[TBL] [Abstract][Full Text] [Related]
19. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
20. Time-dependent evolution of functional vs. remodeling signaling in induced pluripotent stem cell-derived cardiomyocytes and induced maturation with biomechanical stimulation.
Jung G; Fajardo G; Ribeiro AJ; Kooiker KB; Coronado M; Zhao M; Hu DQ; Reddy S; Kodo K; Sriram K; Insel PA; Wu JC; Pruitt BL; Bernstein D
FASEB J; 2016 Apr; 30(4):1464-79. PubMed ID: 26675706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
